Financial Services
Asset Management

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.